Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

Amelia C. McCuea Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USAView further author information

Stephen J. Demarestb Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USAView further author information

Karen J. Froningb Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USAView further author information

Michael J. Hickeyb Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USAView further author information

Stephen Antonysamyb Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USAView further author information

Brian Kuhlmana Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA;c Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USACorrespondence[email protected]

https://orcid.org/0000-0003-4907-9699 View further author information

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date